2011, Number S1
<< Back Next >>
Rev Mex Anest 2011; 34 (S1)
Do antifibrinolytics decrease bleeding or are they an unnecessary expense?
Fernández-Rivera BJ
Language: Spanish
References: 7
Page: 49-51
PDF size: 460.41 Kb.
Text Extraction
No abstract
REFERENCES
Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, Starr NJ, Blackstone EH. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006;34:1608-16.
Klein HG. Immunomodulatory aspects of transfusion: a once and future risk? Anesthesiology 1999;91:861–65.
Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1,188 consecutive patients. Anesth Analg 2008;107:1783–90.
Koster A, Fischer T, Praus M, Haberzettl H, Wolfgang M, Kuebler W, Hetzer R, Kuppe H. Hemostatic Activation and inflammatory response during cardiopulmonary bypass. Anesthesiology 2002;97:837–41.
Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005;129:307–21.
CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomized, placebo-controlled trial. Lancet 2010; DOI:10.1016/S0140- 6736(10)60835-5. Published on line 15.
Brown JR, Birkmeyer NJ, O’Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115:2801–13.
Full text